View Older Stories View More Recent Stories
-
TScan Therapeutics Announces $100 Million Series C Financing
-
Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease
-
IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
-
CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conference
-
DiCE Molecules Announces $80 Million Series C Financing
-
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
-
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
-
Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer
-
Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte
-
Form SC 13G MIRAGEN THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ivantis Recognized For Innovation, Excellence And Company Culture
-
Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway
-
Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
-
Solid Biosciences (SLDB) Announces $90 Million Private Placement of Common Stock
-
Solid Biosciences Announces $90 Million Private Placement
-
Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting
-
RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases
-
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program
-
Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics' Boltbody™ ISAC Platform
-
Form SC 13G Iterum Therapeutics plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
CANbridge Pharmaceuticals Completes $43 Million Series E Financing
-
Saniona publishes its interim report for the third quarter 2020
-
Saniona publishes its interim report for the third quarter 2020
-
Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines
-
Nature’s Toolbox Recruits Pharmaceutical Industry Veteran as Chief Commercial Officer
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
Adagio Medical Raises $42.5 Million In Series E Financing
-
Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
-
Novavax Reports Third Quarter 2020 Financial and Operational Results
-
Novavax Reports Third Quarter 2020 Financial and Operational Results
-
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
-
Cybin Completes Reverse Take-Over Transaction
-
Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company
-
Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
-
Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines
-
RA Capital Management, LP Closes its Second Venture Capital Fund, Raising $461 Million
-
Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline
-
Form SC 13G Cardiff Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eidos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 3 Dyne Therapeutics, Inc. For: Sep 16 Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Colorescience® Announces Successful Completion of $30 Million Debt Financing
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Saniona publishes its interim report for the second quarter 2020
-
Synthego Raises $100 Million to Accelerate CRISPR Platform Scale-up in Response to Growing Demand
-
Kinnate Biopharma Closes $98 Million Series C Financing

